Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03206021 · ClinicalTrials.gov registry record · Phase 1
COZMOS:Phase I/Ib Trial of Combined 5'Azacitidine and Carboplatin for Recurrent/Refractory Pediatric Brain/Solid Tumors
A Phase 1 study, sponsored by The Hospital for Sick Children.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT03206021 is a Phase 1 study that has completed, run by The Hospital for Sick Children. The registered enrollment target is 31 participants.
The verdict
NCT03206021, a Phase 1 study, has completed, sponsored by The Hospital for Sick Children.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
Many pediatric brain and solid tumors have altered epigenetic landscapes, and altered DNA methylation. As such this study is a Phase I/Ib study of combined 5'Azacitidine with an escalating dose of carboplatin for all recurrent/refractory pediatric brain and solid tumors. The phase I component will establish with maximum tolerated dose of carboplatin with azacytidine. An expansion cohort will be recruited of up to 30 patients will follow consisting of 20 recurrent posterior fossa ependymoma and 10 recurrent supratentorial ependymoma.
Interventions
- DRUG 5 Azacytidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2017-08-01 |
| Est. Completion | 2024-03-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03206021
The ClinicalTrials.gov registry entry for NCT03206021 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Hospital for Sick Children, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 5 Azacytidine is the first listed.
NCT03206021 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03206021 about?
NCT03206021 is a clinical study titled "COZMOS:Phase I/Ib Trial of Combined 5'Azacitidine and Carboplatin for Recurrent/Refractory Pediatric Brain/Solid Tumors". Many pediatric brain and solid tumors have altered epigenetic landscapes, and altered DNA methylation. As such this study is a Phase I/Ib study of combined 5'Azacitidine with an escalating dose of carboplatin for all recurrent/refractory pediatric brain and solid tumors. The phase I component will e...
What is the current status of trial NCT03206021?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2017-08-01. Estimated completion is 2024-03-01.
What interventions are being tested in trial NCT03206021?
The interventions under investigation include: 5 Azacytidine (DRUG).
Who is sponsoring clinical trial NCT03206021?
This trial is sponsored by The Hospital for Sick Children, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.